SCHEMBL7189807

SCHEMBL7189807

CCCCC(CC)C[P](=O)c1ccccc1C(=O)c1c(C(F)(F)F)cccc1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP3A4 P08684 1/20 0.41
LMNA P02545 1/20 0.38
PRSS1 P07477 1/20 0.37
PRSS2 P07478 1/20 0.37
PRSS3 P35030 1/20 0.37
GLA P06280 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CTSS P25774 4/20 0.34
CNR2 P34972 5/20 0.34
CTSK P43235 1/20 0.34
F2R P25116 1/20 0.34
SLC6A9 P48067 1/20 0.34
CNR1 P21554 4/20 0.33
PLK1 P53350 1/20 0.33
PLK3 Q9H4B4 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185614 0.84 ALDH1A1 (0.44) CA2ALDH1A1CYP3A4LMNAPRSS1
SCHEMBL7181145 0.84 ALDH1A1 (0.43) CA2ALDH1A1CYP3A4LMNAPRSS1
SCHEMBL7182608 0.82 CNR2 (0.39) CYP3A4LMNATSHRCNR2F2R
SCHEMBL7180550 0.82 LMNA (0.36) ALDH1A1CYP3A4LMNACTSSCTSK
SCHEMBL7182225 0.82 CA2 (0.44) CA2ALDH1A1CYP3A4LMNAPRSS1
SCHEMBL7182845 0.81 ALDH1A1 (0.43) CA2ALDH1A1CYP3A4LMNAPRSS1
SCHEMBL7174994 0.79 ALDH1A1 (0.44) CA2ALDH1A1CYP3A4LMNAPRSS1
SCHEMBL7180883 0.79 ALDH1A1 (0.44) CA2ALDH1A1CYP3A4LMNAPRSS1
SCHEMBL7177874 0.78 SCD (0.36) ALDH1A1LMNACTSSCNR2CTSK
SCHEMBL7183925 0.78 CTSS (0.33) ALDH1A1CYP3A4LMNACTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 CA2 2297/4885ALDH1A1 3416/4885CYP3A4 1652/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 CA2 2346/4885ALDH1A1 3984/4885CYP3A4 1881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.